Publications by authors named "Raye Litten"

Claim this Profile
P
Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial.
Stephanie S O'Malley, Robert Miranda, Sarah W Book, Thomas H Chun, Thomas Liss, Raye Z Litten

Alcohol Alcohol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a novel GABA-B positive allosteric modulator, ASP8062, on alcohol cue-elicited craving and naturalistic alcohol consumption in a multisite randomized, double-blind, placebo-controlled trial.
Joseph P Schacht, Lara A Ray, Robert Miranda, Daniel E Falk, Megan L Ryan, Raye Z Litten

Alcohol Clin Exp Res (Hoboken)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement.
Brian P Lee, Katie Witkiewitz, Jessica Mellinger, Frank A Anania, Ramon Bataller, Raye Litten

Nat Rev Gastroenterol Hepatol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining Recovery From Alcohol Use Disorder: Development of an NIAAA Research Definition.
Brett T Hagman, Daniel Falk, Raye Litten, George F Koob

Am J Psychiatry· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The GABA-B receptor agonist baclofen helps patients with alcohol use disorder: why these findings matter.
Lorenzo Leggio, Raye Z Litten

Neuropsychopharmacology· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies.
Lorenzo Leggio, Daniel E Falk, Megan L Ryan, Joanne Fertig, Raye Z Litten

Handb Exp Pharmacol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom.
Katie Witkiewitz, Nick Heather, Daniel E Falk, Raye Z Litten, Deborah S Hasin

Addiction· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline.
Robert Miranda, Stephanie S O'Malley, Hayley Treloar Padovano, Ran Wu, Daniel E Falk, Raye Z Litten

Alcohol Clin Exp Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice.
Raye Z Litten, Daniel E Falk, Megan L Ryan, Joanne Fertig, Lorenzo Leggio

Alcohol Clin Exp Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Dr. Mark Litt's Commentary.
Raymond F Anton, Katie Witkiewitz, Daniel Falk, Raye Litten, Deborah Hasin

Alcohol Clin Exp Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general population.
Justin Knox, Melanie Wall, Katie Witkiewitz, Henry R Kranzler, Daniel E Falk, Raye Litten

Drug Alcohol Depend· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in Pharmacotherapy Development: Human Clinical Studies.
Raye Z Litten, Daniel E Falk, Megan L Ryan, Joanne Fertig, Lorenzo Leggio

Handb Exp Pharmacol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial.
Katie Witkiewitz, Daniel E Falk, Raye Z Litten, Deborah S Hasin, Henry R Kranzler

Alcohol Clin Exp Res· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population.
Justin Knox, Jennifer Scodes, Melanie Wall, Katie Witkiewitz, Henry R Kranzler, Raye Litten

Drug Alcohol Depend· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
Daniel E Falk, Stephanie S O'Malley, Katie Witkiewitz, Raymond F Anton, Raye Z Litten

JAMA Psychiatry· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.
Daniel E Falk, Megan L Ryan, Joanne B Fertig, Eric G Devine, Ricardo Cruz, Raye Z Litten

Alcohol Clin Exp Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder.
Katie Witkiewitz, Henry R Kranzler, Kevin A Hallgren, Stephanie S O'Malley, Daniel E Falk, Raye Z Litten

Alcohol Clin Exp Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in Nonabstinent WHO Drinking Risk Levels and Change in Risk for Liver Disease and Positive AUDIT-C Scores: Prospective 3-Year Follow-Up Results in the U.S. General Population.
Justin Knox, Melanie Wall, Katie Witkiewitz, Henry R Kranzler, Daniel Falk, Raye Litten

Alcohol Clin Exp Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addictions Neuroclinical Assessment: A reverse translational approach.
Laura E Kwako, Reza Momenan, Erica N Grodin, Raye Z Litten, George F Koob

Neuropharmacology· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article.
Raye Z Litten, Daniel E Falk, Stephanie S O'Malley, Katie A Witkiewitz, Karl F Mann

Alcohol Clin Exp Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population.
Deborah S Hasin, Melanie Wall, Katie Witkiewitz, Henry R Kranzler, Daniel Falk, Raye Litten

Lancet Psychiatry· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the COMBINE Study.
Katie Witkiewitz, Adam D Wilson, Matthew R Pearson, Kevin A Hallgren, Daniel E Falk, Raye Z Litten

Alcohol Clin Exp Res· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Neuroclinical Assessment of Addiction Needs to Incorporate Decision-Making Measures and Ecological Validity.
Laura E Kwako, Reza Momenan, Raye Z Litten, George F Koob, David Goldman

Biol Psychiatry· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Posttreatment Low-Risk Drinking as a Predictor of Future Drinking and Problem Outcomes Among Individuals with Alcohol Use Disorders: A 9-Year Follow-Up.
Andrea H Kline-Simon, Raye Z Litten, Constance M Weisner, Daniel E Falk

Alcohol Clin Exp Res· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels.
Katie Witkiewitz, Kevin A Hallgren, Henry R Kranzler, Karl F Mann, Deborah S Hasin, Raye Z Litten

Alcohol Clin Exp Res· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis